{
}
The SMI index is down in pre-market trading, with all 20 stocks losing ground, although Sandoz shows a slight upswing. Investors are intrigued by Evotec's potential takeover by Halozyme Therapeutics, which has offered €11 per share, causing Evotec's stock to rise to €10.80, despite a significant drop from over €21 at the year's start. Analysts note the high intrinsic value of Evotec is becoming clearer.
Halozyme Therapeutics
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Evotec shares surge amid takeover speculation despite broader market decline
06:14 15.11.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
Banking Regulations
Retail and Consumer Goods
Market Analysis and Predictions
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Energy Sector Developments
Startups & Entrepreneurship
Supply Chain Management
Financial Scams and Security
Government Policies
Central Bank Actions
Domestic Politics
Government Economic Policies
Workplace Trends
Countries:
Companies:
Tesla, Inc.
Barclays PLC
BNP Paribas SA
JPMorgan Chase & Co.
Apple Inc.
Raiffeisen Bank International AG
Deutsche Bank RV Global PP
Bank of America Corporation
UBS Group AG
NVIDIA Corporation
Morgan Stanley
Capital One Financial Corporation
The Goldman Sachs Group, Inc.
Citigroup Inc.
Amazon.com, Inc.
SpaceXCoin USD
Berkshire Hathaway Inc.
Commerzbank AG
Credit Suisse Real Estate Fund Siat
Wells Fargo & Company
Currencies:
United States Dollar
Euro
Chinese Yuan
Indian Rupee
Swiss Franc
British Pound Sterling
Vietnamese Đồng
Japanese Yen
Australian Dollar
Hong Kong Dollar
United Arab Emirates Dirham
Singapore Dollar
Russian Ruble
South Korean Won
Thai Baht
Norwegian Krone
Danish Krone
Swedish Krona
Ghanaian Cedi
Canadian Dollar
People: